Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

International Immunopharmacology

Topics

Biology

Epidemiology

Medicine

Immunology

Molecular Biology

Show all topics

DOI

10.1016/j.intimp.2024.112214